

# Bernd Heinrich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7197076/publications.pdf>

Version: 2024-02-01

28  
papers

2,401  
citations

471371

17  
h-index

610775

24  
g-index

28  
all docs

28  
docs citations

28  
times ranked

3677  
citing authors

#	ARTICLE	IF	CITATIONS
1	The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. <i>Gut</i> , 2022, 71, 1161-1175.	6.1	60
2	NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice. <i>IScience</i> , 2022, 25, 103847.	1.9	12
3	Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. <i>Journal of Hepatology</i> , 2022, 77, 748-760.	1.8	57
4	Innate lymphoid cells at the crossroads of innate and adaptive immunity. <i>Hepatology</i> , 2022, 76, 903-905.	3.6	0
5	Plasticity of Innate Lymphoid Cells in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1
6	Steatohepatitis Impairs T-cell Directed Immunotherapies Against Liver Tumors in Mice. <i>Gastroenterology</i> , 2021, 160, 331-345.e6.	0.6	46
7	Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. <i>Journal of Hepatology</i> , 2021, 74, 700-715.	1.8	60
8	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 112-127.	4.8	159
9	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021, 74, 1145-1154.	1.8	76
10	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021, 11, 1248-1267.	7.7	117
11	Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models. <i>IScience</i> , 2021, 24, 101990.	1.9	11
12	Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1166-1178.	2.3	15
13	Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response. <i>Cancer Immunology Research</i> , 2021, 9, 1024-1034.	1.6	29
14	Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. <i>United European Gastroenterology Journal</i> , 2020, 8, 444-452.	1.6	9
15	Combined locoregional-immunotherapy for liver cancer. <i>Journal of Hepatology</i> , 2019, 70, 999-1007.	1.8	146
16	Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 449-457.	1.8	102
17	Development of shellfish allergy after exposure to dual immune checkpoint blockade. <i>Hepatic Oncology</i> , 2018, 5, HEPO2.	4.2	3
18	Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. <i>Science</i> , 2018, 360, .	6.0	931

#	ARTICLE	IF	CITATIONS
19	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1305-1315.	2.0	93
20	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. <i>Cell Death and Disease</i> , 2018, 9, 620.	2.7	90
21	Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease. <i>Methods and Protocols</i> , 2018, 1, 21.	0.9	14
22	Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 536-554.	8.2	158
23	Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2389-2401.	1.0	36
24	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
25	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. <i>European Journal of Cancer</i> , 2016, 59, 160-170.	1.3	78
26	Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1. <i>Frontiers in Oncology</i> , 2014, 4, 92.	1.3	22
27	Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. <i>OncoTargets and Therapy</i> , 2013, 6, 1119.	1.0	16
28	Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4